Proparacaine HCl Ophthalmic Solution Rx
Generic Name and Formulations:
Proparacaine HCl 0.5%; contains benzalkonium chloride.
Various generic manufacturers
Indications for Proparacaine HCl Ophthalmic Solution:
For procedures in which a topical ophthalmic anesthetic is indicated: corneal anesthesia of short duration (eg, tonometry, gonioscopy, removal of corneal foreign bodies), and for short corneal and conjunctival procedures.
Adults and Children:
Removal of foreign bodies and sutures, and for tonometry: 1–2 drops in each eye before operating. Short corneal and conjunctival procedures: 1 drop in each eye every 5–10 minutes for 5–7 doses.
Not for injection into eye. Permanent corneal opacification with accompanying visual loss with prolonged use. Pregnancy (Cat.C). Nursing mothers.
Rapidly-acting topical anesthetic.
Local effects (eg, stinging, burning, conjunctival redness); rare: severe, immediate-type hyperallergic corneal reaction.
Formerly known under the brand name Ophthetic.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|